Mining a Cathepsin Inhibitor Library for New Antiparasitic Drug Leads

The targeting of parasite cysteine proteases with small molecules is emerging as a possible approach to treat tropical parasitic diseases such as sleeping sickness, Chagas' disease, and malaria. The homology of parasite cysteine proteases to the human cathepsins suggests that inhibitors originally developed for the latter may be a source of promising lead compounds for the former. We describe here the screening of a unique ∼2,100-member cathepsin inhibitor library against five parasite cysteine proteases thought to be relevant in tropical parasitic diseases. Compounds active against parasite enzymes were subsequently screened against cultured Plasmodium falciparum, Trypanosoma brucei brucei and/or Trypanosoma cruzi parasites and evaluated for cytotoxicity to mammalian cells. The end products of this effort include the identification of sub-micromolar cell-active leads as well as the elucidation of structure-activity trends that can guide further optimization efforts.

[1]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[2]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[3]  J. McKerrow,et al.  Cysteine protease inhibitors as chemotherapy for parasitic infections. , 1999, Bioorganic & medicinal chemistry.

[4]  T Niyonsenga,et al.  Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  Conor R. Caffrey,et al.  A Parasite Cysteine Protease Is Key to Host Protein Degradation and Iron Acquisition*S⃞ , 2008, Journal of Biological Chemistry.

[6]  Ashutosh Kumar Singh,et al.  Characterization of Native and Recombinant Falcipain-2, a Principal Trophozoite Cysteine Protease and Essential Hemoglobinase ofPlasmodium falciparum * , 2000, The Journal of Biological Chemistry.

[7]  Neil D. Rawlings,et al.  MEROPS: the peptidase database , 2009, Nucleic Acids Res..

[8]  Michelle R. Arkin,et al.  Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.

[9]  A. Shelat,et al.  Structure-guided development of selective TbcatB inhibitors. , 2009, Journal of medicinal chemistry.

[10]  Sanjay Batra,et al.  Structure-based approach to falcipain-2 inhibitors: synthesis and biological evaluation of 1,6,7-trisubstituted dihydroisoquinolines and isoquinolines. , 2003, Bioorganic & medicinal chemistry.

[11]  M. Sajid,et al.  Cysteine proteases of parasitic organisms. , 2002, Molecular and biochemical parasitology.

[12]  M. Ramjee,et al.  Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery. , 2006, The Biochemical journal.

[13]  J. R. Somoza,et al.  Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. , 2005, Journal of medicinal chemistry.

[14]  P. Rosenthal,et al.  Antimalarial drug discovery: old and new approaches , 2003, Journal of Experimental Biology.

[15]  S. Krishna,et al.  Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance , 2006, Trends in molecular medicine.

[16]  P. Rosenthal,et al.  Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. , 2006, Molecular and biochemical parasitology.

[17]  J. Palmer,et al.  Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. , 1998, Journal of cell science.

[18]  C. Caffrey,et al.  Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-phe-ala-CHN2. , 1999, Experimental parasitology.

[19]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[20]  J. Palmer,et al.  Peptidyl fluoromethyl ketones as inhibitors of cathepsin B. Implication for treatment of rheumatoid arthritis. , 1992, Biochemical pharmacology.

[21]  Frédéric Massé,et al.  Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease. , 2010, Bioorganic & medicinal chemistry letters.

[22]  Ashutosh Kumar Singh,et al.  Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. , 2001, The Biochemical journal.

[23]  R J Fletterick,et al.  The crystal structure of cruzain: a therapeutic target for Chagas' disease. , 1995, Journal of molecular biology.

[24]  J. Falgueyret,et al.  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.

[25]  I. Bathurst,et al.  Medicines for Malaria Venture: sustaining antimalarial drug development. , 2006, Trends in parasitology.

[26]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[27]  P. Rosenthal,et al.  Cysteine proteases of malaria parasites. , 2004, International journal for parasitology.

[28]  J. Palmer,et al.  Keto-1,3,4-oxadiazoles as cathepsin K inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[29]  J. McKerrow,et al.  RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model , 2008, PLoS neglected tropical diseases.

[30]  K N Houk,et al.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.

[31]  Kelly Chibale,et al.  Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. , 2004, Journal of medicinal chemistry.

[32]  I. Gilbert,et al.  Target assessment for antiparasitic drug discovery. , 2007, Trends in parasitology.

[33]  P. Rosenthal,et al.  Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. G. Davey.  Chemotherapy of malaria. , 1951, British medical bulletin.

[35]  M. Bogyo,et al.  Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. , 2001, Molecular and biochemical parasitology.

[36]  William R. Roush,et al.  Structure-Activity Relationships for Inhibition of Cysteine Protease Activity and Development of Plasmodium falciparum by Peptidyl Vinyl Sulfones , 2003, Antimicrobial Agents and Chemotherapy.

[37]  P. Rosenthal,et al.  A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. , 1988, The Journal of clinical investigation.

[38]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[39]  Jun Liu,et al.  Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Fletterick,et al.  Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi. , 1993, The Journal of biological chemistry.

[41]  C. Bryant,et al.  Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors. , 2002, Bioorganic & medicinal chemistry.

[42]  G. Rishton.  Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[43]  Michele Connelly,et al.  Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. , 2008, Journal of medicinal chemistry.

[44]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[45]  Adam R Renslo,et al.  Drug discovery and development for neglected parasitic diseases , 2006, Nature chemical biology.

[46]  Juan Miguel,et al.  Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. , 2010, Journal of medicinal chemistry.

[47]  J. Gut,et al.  Comparison of the antiplasmodial and falcipain-2 inhibitory activity of beta-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids. , 2010, Bioorganic & medicinal chemistry letters.

[48]  A. Fairlamb,et al.  Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. , 2003, The Biochemical journal.

[49]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection , 2007, Antimicrobial Agents and Chemotherapy.

[50]  Beth Apsel,et al.  Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei , 2006, Chemical biology & drug design.